Reinier de Graaf Groep
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Cardiology department at Reinier de Graaf Groep is dedicated to advancing care for patients with atherosclerotic cardiovascular disease, atrial fibrillation, and related vascular conditions. Ongoing studies aim to test innovative lipid‑lowering therapies, evaluate safer anticoagulation options, and assess novel agents that target high‑risk heart and stroke outcomes.
- Emerging RNA‑based lipid‑modifying treatments
- Next‑generation antithrombotic strategies
- Integrated risk‑reduction programs for primary prevention
- Biomarker‑driven personalization of cardiovascular therapy
The site currently supports 17 active trials with 33 investigators, reflecting a strong focus on cardiovascular innovation.
Female Urogenital Diseases and Pregnancy Complications
Research at the hospital explores solutions for unexplained subfertility and improves outcomes for women undergoing assisted reproduction. Studies investigate hormonal support regimens and cost‑effective adjuncts to increase live‑birth rates, while also evaluating preventive strategies for reproductive tract lesions.
- Hormonal optimization in intra‑uterine insemination
- Non‑invasive diagnostics for early uterine pathology
- Vaccination approaches to reduce vulvar intraepithelial lesions
These initiatives complement the broader clinical portfolio, contributing to the 17 trials conducted at the site.
Neoplasms
The oncology focus includes trials for breast cancer, colon and gastric malignancies, prostate cancer, and lymphomas. Efforts are directed toward evaluating adjuvant endocrine therapies, assessing the impact of low‑dose aspirin on cancer survival, and testing targeted agents that may improve disease‑free survival after standard treatment.
- Adjuvant endocrine therapy versus standard care in early breast cancer
- Low‑dose aspirin as a preventive measure in colorectal cancer recurrence
- Immunotherapy consolidation for high‑risk diffuse large B‑cell lymphoma
- Novel radioligand therapy for metastatic prostate cancer
The oncology program benefits from the multidisciplinary expertise of the 33 investigators across 17 active studies.
Nutritional and Metabolic Diseases
Studies targeting metabolic health address obesity, overweight status, and severe hypertriglyceridemia. Clinical work evaluates agents that lower triglyceride levels, reduce lipoprotein(a), and support weight management, with the goal of decreasing cardiovascular risk in metabolically challenged patients.
- Triglyceride‑lowering therapies for high‑risk ASCVD patients
- Lipoprotein(a) reduction strategies using antisense technology
- Integrated lifestyle and pharmacologic interventions for obesity
These metabolic investigations form a key component of the site’s 17 clinical trials, driven by a team of 33 investigators.
Virus Diseases
While the primary focus remains cardiovascular and oncologic research, the centre also supports exploratory work on viral infections that intersect with chronic disease management. Efforts include assessing the impact of viral triggers on cardiovascular events and evaluating vaccination strategies for virus‑related malignancies.
- Influence of chronic viral infections on atherosclerosis progression
- Preventive vaccination in patients with virus‑associated cancers
- Antiviral adjuncts to reduce cardiovascular complications
This niche area adds breadth to the overall research portfolio encompassing 17 trials and 33 investigators.
Reproductive and Urinary Physiological Phenomena
Investigations under this theme examine normal and altered physiological processes of the reproductive and urinary systems. Projects aim to refine diagnostic markers for early detection of urinary disorders and to understand hormonal cycles that affect fertility outcomes.
- Biomarkers for early identification of urinary tract dysfunction
- Hormonal profiling to predict successful assisted reproduction
- Non‑invasive imaging techniques for reproductive health assessment
These studies complement the broader clinical trial landscape at Reinier de Graaf Groep, contributing to the total of 17 active trials overseen by 33 investigators.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 16 therapeutic areas and 15 of 182 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 182 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Reinier de Graaf Groep
lock Showing 1 of 67 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 182 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Venetoclax | 7 | Unknown | 2016-10-27 | 2025-03-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.